Literature DB >> 33352692

Brain Site-Specific Inhibitory Effects of the GLP-1 Analogue Exendin-4 on Alcohol Intake and Operant Responding for Palatable Food.

Kayla J Colvin1, Henry S Killen1, Maxwell J Kanter1, Maximilian C Halperin1, Liv Engel1, Paul J Currie1.   

Abstract

Approximately 14.4 million Americans are experiencing alcohol use disorder (AUD) and about two-thirds of people who experience drug addiction will relapse, highlighting the need to develop novel and effective treatments. Glucagon-like peptide-1 (GLP-1) is a peptide hormone implicated in the mesocorticolimbic reward system and has become a peptide of interest with respect to its putative inhibitory effects on drug reward. In order to further develop treatments for those diagnosed with AUD, the interplay between GLP-1 receptor signaling and ethanol consumption must be elucidated. In the present study, we investigated the ability of the GLP-1 analogue, exendin-4 (Ex-4), to alter alcohol intake and operant responding for sucrose pellets in order to further understand the role of this compound in mediating reward. We selected multiple sites throughout the prosencephalic and mesencephalic regions of the brain, where we directly administered various doses of Ex-4 to male Sprague Dawley rats. In alcohol investigations, we utilized a two-bottle choice intermittent access protocol. In separate groups of rats, we adopted an operant paradigm in order to examine the effect of Ex-4 on motivated responding for palatable food. Results indicated that GLP-1 receptor signaling effectively suppressed voluntary alcohol intake when injected into the ventral tegmental area (VTA), the accumbens core (NAcC) and shell (NAcS), the dorsomedial hippocampus (DMHipp), and the lateral hypothalamus (LH), which are all structures linked to brain reward mechanisms. The arcuate nucleus (ARcN) and the paraventricular nucleus (PVN) of the hypothalamus were unresponsive, as was the basolateral amygdala (BLA). However, Ex-4 treatment into the ArcN and PVN suppressed operant responding for sucrose pellets. In fact, the VTA, NAcC, NAcS, LH, and the DMHipp all showed comparable suppression of sucrose responding. Overall, our findings suggest that these central structures are implicated in brain reward circuitry, including alcohol and appetitive motivation, which may be mediated by GLP-1 receptor mechanisms. GLP-1, therefore, may play a critical role in modifying addictive behaviors via activation of multiple GLP-1 systems throughout the brain.

Entities:  

Keywords:  appetitive behavior; ethanol; exendin-4; glucagon-like peptide 1; mesocorticolimbic; mesolimbic; reward

Mesh:

Substances:

Year:  2020        PMID: 33352692      PMCID: PMC7766977          DOI: 10.3390/ijms21249710

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  64 in total

Review 1.  Building better strategies to develop new medications in Alcohol Use Disorder: Learning from past success and failure to shape a brighter future.

Authors:  Nazzareno Cannella; Massimo Ubaldi; Alessio Masi; Massimo Bramucci; Marisa Roberto; Angelo Bifone; Roberto Ciccocioppo
Journal:  Neurosci Biobehav Rev       Date:  2019-05-18       Impact factor: 8.989

2.  Glucagon-like peptide-1 in the rat brain: distribution of expression and functional implication.

Authors:  Guibao Gu; Barbara Roland; Kevin Tomaselli; Carrie S Dolman; Carolyn Lowe; Joseph S Heilig
Journal:  J Comp Neurol       Date:  2013-07-01       Impact factor: 3.215

3.  Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain.

Authors:  Kristy M Heppner; Melissa Kirigiti; Anna Secher; Sarah Juel Paulsen; Rikley Buckingham; Charles Pyke; Lotte B Knudsen; Niels Vrang; Kevin L Grove
Journal:  Endocrinology       Date:  2015-01       Impact factor: 4.736

4.  Glucagon-like peptide-1 (GLP-1) receptor agonist prevents development of tolerance to anti-anxiety effect of ethanol and withdrawal-induced anxiety in rats.

Authors:  Ajaykumar N Sharma; Ashish Pise; Jay N Sharma; Praveen Shukla
Journal:  Metab Brain Dis       Date:  2014-11-08       Impact factor: 3.584

5.  Effects of the GLP-1 Agonist Exendin-4 on Intravenous Ethanol Self-Administration in Mice.

Authors:  Gunnar Sørensen; S Barak Caine; Morgane Thomsen
Journal:  Alcohol Clin Exp Res       Date:  2016-08-31       Impact factor: 3.455

6.  The Basolateral Amygdala to Nucleus Accumbens Core Circuit Mediates the Conditioned Reinforcing Effects of Cocaine-Paired Cues on Cocaine Seeking.

Authors:  Mickaël Puaud; Alejandro Higuera-Matas; Paul Brunault; Barry J Everitt; David Belin
Journal:  Biol Psychiatry       Date:  2020-08-05       Impact factor: 13.382

Review 7.  GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence.

Authors:  Elisabet Jerlhag
Journal:  Neuropharmacology       Date:  2018-01-12       Impact factor: 5.250

Review 8.  Basolateral amygdala and stress-induced hyperexcitability affect motivated behaviors and addiction.

Authors:  B M Sharp
Journal:  Transl Psychiatry       Date:  2017-08-08       Impact factor: 6.222

9.  The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents.

Authors:  Daniel Vallöf; Paola Maccioni; Giancarlo Colombo; Minja Mandrapa; Julia Winsa Jörnulf; Emil Egecioglu; Jörgen A Engel; Elisabet Jerlhag
Journal:  Addict Biol       Date:  2015-08-25       Impact factor: 4.280

10.  Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial.

Authors:  Kerstin K Antonsen; Mette K Klausen; Amanda S Brunchmann; Nina le Dous; Mathias E Jensen; Kamilla Woznica Miskowiak; Patrick M Fisher; Gerda K Thomsen; Henrik Rindom; Thomas P Fahmy; Sabine Vollstaedt-Klein; Helene Benveniste; Nora D Volkow; Ulrik Becker; Claus Ekstrøm; Gitte Moos Knudsen; Tina Vilsbøll; Anders Fink-Jensen
Journal:  BMJ Open       Date:  2018-07-16       Impact factor: 2.692

View more
  4 in total

Review 1.  A novel approach to treating opioid use disorders: Dual agonists of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors.

Authors:  Riley Merkel; Amanda Moreno; Yafang Zhang; Rachel Herman; Jennifer Ben Nathan; Sana Zeb; Suditi Rahematpura; Kamryn Stecyk; Brandon T Milliken; Matthew R Hayes; Robert P Doyle; Heath D Schmidt
Journal:  Neurosci Biobehav Rev       Date:  2021-10-29       Impact factor: 8.989

Review 2.  The role of glucagon-like peptide 1 (GLP-1) in addictive disorders.

Authors:  Mette Kruse Klausen; Morgane Thomsen; Gitta Wortwein; Anders Fink-Jensen
Journal:  Br J Pharmacol       Date:  2022-02       Impact factor: 9.473

3.  Peptides for Health Benefits 2020.

Authors:  Cristina Martínez-Villaluenga; Blanca Hernández-Ledesma
Journal:  Int J Mol Sci       Date:  2022-06-16       Impact factor: 6.208

4.  An Overview of Appetite-Regulatory Peptides in Addiction Processes; From Bench to Bed Side.

Authors:  Olesya T Shevchouk; Maximilian Tufvesson-Alm; Elisabet Jerlhag
Journal:  Front Neurosci       Date:  2021-12-09       Impact factor: 4.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.